Wall Street Zen Downgrades Sol-Gel Technologies (NASDAQ:SLGL) to Hold

Sol-Gel Technologies (NASDAQ:SLGL) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Sol-Gel Technologies in a research report on Wednesday, October 8th. Zacks Research raised shares of Sol-Gel Technologies to a “hold” rating in a research note on Tuesday, October 28th. Finally, HC Wainwright boosted their target price on Sol-Gel Technologies from $6.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, October 27th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Sol-Gel Technologies currently has an average rating of “Hold” and a consensus target price of $50.00.

Sol-Gel Technologies Price Performance

Shares of NASDAQ:SLGL opened at $35.54 on Friday. The business’s 50 day moving average price is $31.54 and its 200-day moving average price is $17.12. The firm has a market capitalization of $99.01 million, a PE ratio of -28.89 and a beta of 1.29. Sol-Gel Technologies has a 1 year low of $4.01 and a 1 year high of $52.26.

Sol-Gel Technologies (NASDAQ:SLGL) last announced its quarterly earnings data on Friday, August 15th. The company reported $4.17 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $4.84. The company had revenue of $17.26 million for the quarter, compared to analyst estimates of $2.86 million. Sol-Gel Technologies had a negative return on equity of 11.80% and a negative net margin of 14.25%. As a group, analysts expect that Sol-Gel Technologies will post -0.28 earnings per share for the current year.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.